“Optical Coherence Tomography Predictors of Risk for Progression to Non-Neovascular Atrophic Age-Related Macular Degeneration.”, Ophthalmology, vol. 124, no. 12, pp. 1764-1777, 2017.
, “Peripheral Retinal Changes Associated with Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 12 by the Age-Related Eye Disease Study 2 Optos PEripheral RetinA (OPERA) Study Research G”, Ophthalmology, vol. 124, no. 4, pp. 479-487, 2017.
, “The Association of Statin Use with Cataract Progression and Cataract Surgery: The AREDS2 Report Number 8.”, Ophthalmology, vol. 123, no. 4, pp. 916-7, 2016.
, “A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.”, Ophthalmology, vol. 123, no. 4, pp. 841-9, 2016.
, “EFFECTIVENESS OF DIFFERENT MONITORING MODALITIES IN THE DETECTION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The Home Study, Report Number 3.”, Retina, vol. 36, no. 8, pp. 1542-7, 2016.
, “Evaluating the Validity of the Age-Related Eye Disease Study Grading Scale for Age-Related Macular Degeneration: AREDS2 Report 10.”, JAMA Ophthalmol, vol. 134, no. 9, pp. 1041-7, 2016.
, “Optical Coherence Tomography Reflective Drusen Substructures Predict Progression to Geographic Atrophy in Age-related Macular Degeneration.”, Ophthalmology, vol. 123, no. 12, pp. 2554-2570, 2016.
, “The Association of Dietary Lutein plus Zeaxanthin and B Vitamins with Cataracts in the Age-Related Eye Disease Study: AREDS Report No. 37.”, Ophthalmology, vol. 122, no. 7, pp. 1471-9, 2015.
, “The Association of Statin Use with Age-Related Macular Degeneration Progression: The Age-Related Eye Disease Study 2 Report Number 9.”, Ophthalmology, vol. 122, no. 12, pp. 2490-6, 2015.
, “Changes in lens opacities on the age-related eye disease study grading scale predict progression to cataract surgery and vision loss: age-related eye disease study report no. 34.”, Ophthalmology, vol. 122, no. 5, pp. 888-96, 2015.
, “Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial.”, Am J Ophthalmol, vol. 159, no. 4, pp. 659-666.e1, 2015.
, “Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial.”, JAMA, vol. 314, no. 8, pp. 791-801, 2015.
, “Impairments in Dark Adaptation Are Associated with Age-Related Macular Degeneration Severity and Reticular Pseudodrusen.”, Ophthalmology, vol. 122, no. 10, pp. 2053-62, 2015.
, “Effect of long-chain ω-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.”, JAMA Intern Med, vol. 174, no. 5, pp. 763-71, 2014.
, “Experimental design issue for assessment of carotenoids lutein and zeaxanthin in age-related eye disease study 2 formulation for age-related macular degeneration--reply.”, JAMA Ophthalmol, vol. 132, no. 7, pp. 904-5, 2014.
, “Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial.”, Invest Ophthalmol Vis Sci, vol. 56, no. 1, pp. 330-8, 2014.
, “No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38.”, Ophthalmology, vol. 121, no. 11, pp. 2173-80, 2014.
, “Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study.”, Ophthalmology, vol. 121, no. 2, pp. 535-44, 2014.
, “Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design - HOME Study report number 1.”, Contemp Clin Trials, vol. 37, no. 2, pp. 294-300, 2014.
, “Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.”, JAMA Ophthalmol, vol. 132, no. 2, pp. 142-9, 2014.
, “Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36.”, JAMA Ophthalmol, vol. 132, no. 3, pp. 272-7, 2014.
, “Visual acuity after cataract surgery in patients with age-related macular degeneration: age-related eye disease study 2 report number 5.”, Ophthalmology, vol. 121, no. 6, pp. 1229-36, 2014.
, “Evaluation of optimized digital fundus reflex photographs for lens opacities in the age-related eye disease study 2: AREDS2 report 7.”, Invest Ophthalmol Vis Sci, vol. 54, no. 9, pp. 5989-94, 2013.
, “Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35.”, Ophthalmology, vol. 120, no. 8, pp. 1604-11.e4, 2013.
, “Medical characteristics of patients with macular telangiectasia type 2 (MacTel Type 2) MacTel project report no. 3.”, Ophthalmic Epidemiol, vol. 20, no. 2, pp. 109-13, 2013.
,